Pulse Biosciences CS (PLSE)

$25.77 +0.93 (3.74%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	1.72B
Revenue (ttm)	350,000.00
Net Income (ttm)	-72.78M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20,794.29%
Debt to Equity Ratio	0.00

Volume	218,600
Avg Vol	315,578
Day's Range	N/A - N/A
Shares Out	69.21M
Stochastic %K	44%
Beta	1.65
Analysts	Strong Sell
Price Target	$30.67

Company Profile

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment c...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 510 906 4600

Website: www.pulsebiosciences.com

Address:

601 Brickell Key Drive, Suite 1080, Miami, United States

LeisureSuitLarry Jun. 9 at 8:00 PM

$PLSE

0 · Reply

TruthBroker2 Jun. 7 at 10:55 PM

$PLSE .

0 · Reply

TruthBroker2 Jun. 6 at 2:53 PM

$SMMT $PLSE .

0 · Reply

Doozio Jun. 4 at 11:10 PM

Chop chop huckleberries $PROF da 🧠 has a $PLSE ONTO 🐒🍌🧠⏰♾️

1 · Reply

LeisureSuitLarry Jun. 4 at 4:12 PM

$PLSE looks great

0 · Reply

bob2013 Jun. 4 at 3:45 PM

$PLSE On June 04, 2026, Canaccord Genuity initiated coverage of Pulse Biosciences Inc PLSE +10.62% 32 , assigning it a Buy rating with a price target of $32. The firm emphasized Pulse's innovative cardiac ablation technology tailored for electrophysiologists. The electrophysiology ablation market is projected to reach approximately $3 billion, growing at an annual rate of 10% to 15%. Analysts believe that Pulse Biosciences' unique nanosecond pulsed field ablation technology could capture a significant share of this expanding market.

0 · Reply